Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics is offering 19,730,000 shares of common stock and pre-funded warrants to purchase up to 1,400,000 additional shares. The offering price is $17.75 per share and each pre-funded warrant has an exercise price of $0.001 per share. The company estimates net proceeds of approximately $352.1 million, which it intends to use to advance the clinical development of abdakibart (AVTX-009) into a Phase 3 registrational program, for working capital and general corporate purposes. Avalo reported $82.0 million of cash, cash equivalents and short-term investments as of March 31, 2026. The pre-funded warrants are non‑expiring, subject to ownership limits (4.99% default; holder may elect 9.99%), and are not expected to be listed.
AVTX-related sale notice: A broker-dealer filing lists 54,508 shares of Common Stock to be sold on 05/06/2026 pursuant to an exercise of stock options for cash. The filing also lists recent 10b5-1 programmed sales by Mittie Doyle totaling multiple transactions during March–May 2026.
AVTX reported proposed transactions relating to company common stock. The filing lists an exercise of stock options for 47,000 shares on 05/06/2026 (cash to issuer) and records recent 10b5-1 sales of 8,457, 8,458, 7,980, and 7,979 shares on 04/30/2026, 04/29/2026, 04/02/2026, and 04/01/2026 respectively, with dollar proceeds shown for each sale.
Avalo Therapeutics ownership disclosure: FMR LLC (and Abigail P. Johnson in a related capacity) reports beneficial ownership of 2,879,481 shares of common stock, representing 12.6% of the class in an Amendment No. 1 to a Schedule 13G/A.
The filing lists sole dispositive power and, where applicable, sole voting power tied to the reported shares. Signatures are dated 05/05/2026.
Avalo Therapeutics is offering shares of its common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable for common stock, subject to 4.99% (or, at holder election, 9.99%) ownership limits. The company reported positive Phase 2 topline results for abdakibart in HS and lists common stock on Nasdaq under AVTX. The prospectus describes underwriting arrangements, an underwriter option to purchase additional shares, intended use of proceeds to advance abdakibart into Phase 3, and a preliminary cash position of approximately $82.0 million as of March 31, 2026.
Avalo Therapeutics reported positive topline Phase 2 LOTUS data for abdakibart (AVTX-009) in moderate to severe hidradenitis suppurativa. The 253‑patient randomized, placebo-controlled trial met its primary endpoint, with HiSCR75 response rates of 42.2% and 42.9% at Week 16 versus 25.6% for placebo.
Key secondary measures, including HiSCR50, International HS Severity Score System (IHS4) and draining tunnel count, were statistically significant or numerically favorable, and responses were similar in patients with and without prior biologic use. Abdakibart was well tolerated, with treatment-emergent adverse event rates comparable to placebo and no neutropenia, serious or opportunistic infections. Avalo plans to advance abdakibart into a registrational Phase 3 program in HS.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan sold 16,915 shares of common stock in open-market transactions. He sold 8,458 shares on April 29, 2026 at an average price of $13.0925 and 8,457 shares on April 30, 2026 at an average price of $13.2261. The sales were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025, with actual prices ranging from $12.61 to $13.54. Following these transactions, he directly holds 423 shares, down from 17,338 shares before the sales.
AVTX insider filed a Form 144 reporting a proposed sale of 16,915 restricted stock units. The filing lists Morgan Stanley Smith Barney LLC as the broker. It also reports executed 10b5-1 sales of 7,979 shares on 04/01/2026 for $133,770.33 and 7,980 shares on 04/02/2026 for $136,822.69.